Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.76
(-1.43%)
CAD 2.76
(-1.43%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 46.72 Million USD | -9.35% |
| 2022 | 51.54 Million USD | 2.48% |
| 2021 | 50.3 Million USD | 21.88% |
| 2020 | 41.27 Million USD | 35.4% |
| 2019 | 30.48 Million CAD | 94.6% |
| 2018 | 15.66 Million CAD | 156.81% |
| 2017 | 6.09 Million CAD | 19.13% |
| 2016 | 5.11 Million CAD | -3.07% |
| 2015 | 5.28 Million CAD | 7.72% |
| 2014 | 4.9 Million CAD | -39.48% |
| 2013 | 8.1 Million CAD | 5316.97% |
| 2012 | 149.56 Thousand CAD | 109759.6% |
| 2011 | 136.14 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.5 Million USD | 0.24% |
| 2023 Q4 | 10.48 Million USD | -5.8% |
| 2023 Q3 | 11.12 Million USD | -12.57% |
| 2023 Q2 | 12.72 Million USD | 2.63% |
| 2023 Q1 | 12.39 Million USD | 1.71% |
| 2023 FY | 46.72 Million USD | -9.35% |
| 2022 Q1 | 12.91 Million USD | 19.38% |
| 2022 Q2 | 13.81 Million USD | 7.0% |
| 2022 Q3 | 12.66 Million USD | -8.35% |
| 2022 Q4 | 12.19 Million USD | -3.72% |
| 2022 FY | 51.54 Million USD | 2.48% |
| 2021 FY | 50.3 Million USD | 21.88% |
| 2021 Q2 | 13.59 Million USD | -3.49% |
| 2021 Q3 | 11.8 Million USD | -13.15% |
| 2021 Q1 | 14.08 Million USD | 26.82% |
| 2021 Q4 | 10.81 Million USD | -8.4% |
| 2020 Q3 | 10.83 Million CAD | 18.75% |
| 2020 Q4 | 11.1 Million USD | 2.47% |
| 2020 Q2 | 9.12 Million CAD | 0.29% |
| 2020 Q1 | 9.1 Million CAD | 50.5% |
| 2020 FY | 41.27 Million USD | 35.4% |
| 2019 Q1 | 8.41 Million CAD | 19.08% |
| 2019 Q3 | 7.63 Million CAD | -7.25% |
| 2019 Q2 | 8.23 Million CAD | -2.22% |
| 2019 FY | 30.48 Million CAD | 94.6% |
| 2019 Q4 | 6.04 Million CAD | -20.79% |
| 2018 Q1 | 1.63 Million CAD | 10.52% |
| 2018 Q4 | 7.06 Million CAD | 20.35% |
| 2018 FY | 15.66 Million CAD | 156.81% |
| 2018 Q3 | 5.87 Million CAD | 46.63% |
| 2018 Q2 | 4 Million CAD | 144.92% |
| 2017 Q1 | 1.64 Million CAD | 17.43% |
| 2017 Q3 | 1.49 Million CAD | 4.04% |
| 2017 Q4 | 1.47 Million CAD | -1.25% |
| 2017 FY | 6.09 Million CAD | 19.13% |
| 2017 Q2 | 1.44 Million CAD | -12.36% |
| 2016 Q2 | 1.37 Million CAD | -50.97% |
| 2016 FY | 5.11 Million CAD | -3.07% |
| 2016 Q1 | 2.8 Million CAD | 90.75% |
| 2016 Q4 | 1.39 Million CAD | 11.81% |
| 2016 Q3 | 1.25 Million CAD | -9.05% |
| 2015 FY | 5.28 Million CAD | 7.72% |
| 2015 Q4 | 1.47 Million CAD | 14.46% |
| 2015 Q3 | 1.28 Million CAD | 0.64% |
| 2015 Q2 | 1.27 Million CAD | -20.7% |
| 2015 Q1 | 1.61 Million CAD | 1120.48% |
| 2014 Q1 | 1.6 Million CAD | 0.0% |
| 2014 FY | 4.9 Million CAD | -39.48% |
| 2014 Q4 | -157.87 Thousand CAD | -108.97% |
| 2014 Q2 | 1.9 Million CAD | 18.18% |
| 2014 Q3 | 1.76 Million CAD | -7.38% |
| 2013 Q3 | 1.21 Million CAD | 7253.26% |
| 2013 FY | 8.1 Million CAD | 5316.97% |
| 2013 Q1 | 1995.89 CAD | -79.78% |
| 2013 Q2 | 16.47 Thousand CAD | 725.44% |
| 2012 Q4 | 9870.76 CAD | -99.13% |
| 2012 Q1 | 29.75 Thousand CAD | -68.51% |
| 2012 Q3 | 1.13 Million CAD | 47544.66% |
| 2012 FY | 149.56 Thousand CAD | 109759.6% |
| 2012 Q2 | 2383.54 CAD | -91.99% |
| 2011 Q4 | 94.47 Thousand CAD | 0.0% |
| 2011 FY | 136.14 CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aurora Cannabis Inc. | 158.53 Million CAD | 70.526% |
| Avicanna Inc. | 14.59 Million CAD | -220.23% |
| Avant Brands Inc. | 5.65 Million CAD | -725.711% |
| Cardiol Therapeutics Inc. | 29.53 Million CAD | -58.197% |
| Crescita Therapeutics Inc. | 12.32 Million CAD | -279.278% |
| Knight Therapeutics Inc. | 155.54 Million CAD | 69.959% |
| MediPharm Labs Corp. | 23.08 Million CAD | -102.43% |
| OrganiGram Holdings Inc. | 277.81 Million CAD | 83.18% |
| Canopy Growth Corporation | 308.61 Million CAD | 84.859% |
| Willow Biosciences Inc. | 7.55 Million CAD | -518.573% |
| Auxly Cannabis Group Inc. | 40.28 Million CAD | -16.0% |